UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

	ed by the Registrant 🗵				
File	ed by a Party other than the Registrant 🗆				
Che	eck the appropriate box:				
	Preliminary Proxy Statement				
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))				
	□ Definitive Proxy Statement				
\times	Definitive Additional Materials				
	Soliciting Material Pursuant to §240.14a-12				
	SAREPTA THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter)				
D	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)				
	ment of Filing Fee (Check the appropriate box):				
×	when of Filing Fee (Check the appropriate box): No fee required.				
	whent of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials.				
×	when of Filing Fee (Check the appropriate box): No fee required.				
	whent of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials.				
	whent of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials.				
	whent of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials.				
	whent of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials.				



Online

Go to www.envisionreports.com/SRPT or scan the QR code — login details are located in the shaded bar below.

Stockholder Meeting Notice

Important Notice Regarding the Availability of Proxy Materials for the Sarepta Therapeutics, Inc. Meeting to be Held on June 6, 2024

Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholder meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and annual report to stockholders are available at:

www.envisionreports.com/SRPT



Easy Online Access — View your proxy materials and vote.

Step 1: Go to www.envisionreports.com/SRPT.

Step 2: Click on Cast Your Vote or Request Materials.

Step 3: Follow the instructions on the screen to log in.

Step 4: Make your selections as instructed on each screen for your delivery preferences.

2 N O T

Step 5: Vote your shares.

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.



Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 27, 2024 to facilitate timely delivery.



Stockholder Meeting Notice

Sarepta Therapeutics, Inc.'s Annual Meeting of Stockholders will be held on June 6, 2024 at 10:00 a.m. Eastern Time, virtually via the internet at meetnow.global/MZXJRRN. To access the meeting you must have the 15 digit number that is printed in the oval shaded bar located on the reverse side of this notice.

Proposals to be voted on at the meeting are listed below along with the Board of Directors' recommendations.

The Board of Directors recommends a vote "FOR" all the nominees listed and "FOR" Proposals 2 and 3.

- 1. TO ELECT, AS CLASS I DIRECTORS TO HOLD OFFICE UNTIL THE 2026 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: DOUGLAS S. INGRAM, HANS WIGZELL, M.D. PH.D., KATHRYN J. BOOR, PH.D., MICHAEL CHAMBERS
- 2. ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION
- 3. RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT YEAR ENDING DECEMBER 31, 2024

PLEASE NOTE - YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please have your 15 digit number available when accessing the virtual meeting website.



Here's how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current meeting materials.

PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

- Internet Go to www.envisionreports.com/SRPT. Click Cast Your Vote or Request Materials.
- Phone Call us free of charge at 1-866-641-4276.
- Email Send an email to investorvote@computershare.com with "Proxy Materials Sarepta Therapeutics, Inc." in the subject line.
 Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 27, 2024.